---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-106646"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:37:23.566952+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review

## Summary
- Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.
- Decision follows data monitoring committee evaluation of full Reliance II dataset.
- Will continue advancing Phase 1 study of REL-P11, a metabolic disease investigational agent.
- Commenced process to explore strategic alternatives including sale, merger, or asset acquisition.
- Engaging financial advisor; no timetable set for completion of strategic review.

## SEC filing metadata
- accession: 0001213900-24-106646
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/0001213900-24-106646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/ea0224026-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-106646
- JSON: https://secwatch.observer/filing/0001213900-24-106646.json
- Plain text: https://secwatch.observer/filing/0001213900-24-106646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.